Navigation Links
Maxygen Reports Fourth Quarter and Year End 2007 Financial Results
Date:2/12/2008

nts. These and other risk factors are more fully discussed in our Form 10-K for the year ended December 31, 2006, including under the caption "Risk Factors", and in our other periodic SEC reports, all of which are available from Maxygen at http://www.maxygen.com. Maxygen disclaims any obligation to update or revise any forward-looking statement contained in this release as a result of new information or future events or developments.

Selected Consolidated Financial Information

Condensed Consolidated Statements of Operations

(in thousands, except per share amounts)

Three Months Ended Twelve Months Ended

December 31, December 31,

2007 2006 2007 2006

(unaudited) (unaudited) (Note 1)

Revenues:

Collaborative research and

development revenue $1,756 $5,326 $10,232 $20,544

Revenue from related party 7,696 -- 8,286 --

Grant revenue 1,529 1,184 4,639 4,477

Total revenues 10,981 6,510 23,157 25,021

Expenses:

Research and development 15,338 13,636 59,851 49,130

General and administrative 3,141 4,629 14,951 17,559

Restructuring charges 5,212 -- 5,212 --

Total operating expenses 23,691 18,265 80,014 66,689

Loss from operations (12,710)(11,755) (56,857) (41,668)

Interest income and other

(expense), net 1,436 2,433 7,542 8,524

Equity in net losses of minority

interests -- --
'/>"/>

SOURCE Maxygen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Maxygen to Present at the Roth 20th Annual OC Growth Stock Conference
2. Maxygen to Present at the Stanford Group Company 13th Annual Healthcare Conference
3. Maxygen to Present at the JPMorgan 26th Annual Healthcare Conference
4. Maxygen Licenses Dengue Vaccine Technology to sanofi pasteur
5. Maxygen Reports Third Quarter 2007 Financial Results
6. Maxygen Announces Upcoming Webcasts at Investor Conferences
7. Maxygen Third Quarter 2007 Financial Results Conference Call Notice
8. Maxygen Announces Hold on MAXY-alpha Development Program
9. Cynosure Reports Record Revenues and Net Income for the Fourth Quarter of 2007
10. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
11. Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... "The interface is the device," Nobel laureate Herbert ... to be found at the junctures where layers ... of nanotechnology, the interfaces between layers of metal ... such high-tech favorites as spintronics, high-temperature superconductors, ferroelectrics ...
(Date:1/15/2014)... 15, 2014 Look inside the new ... for the lab, from fluid handling to instruments to ... ship when you order. , Preferred Solutions features ... from the L/S® model for precise flow control and ...
(Date:1/15/2014)... January 15, 2014 This webinar will ... and clinical safety assessment in biosimilars. , Regulatory frameworks ... biosimilar drug development, however the complex nature of biopharmaceuticals ... safety and efficacy extremely challenging. Based on the specific ...
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains how ... latent viruses is the Epstein Barr Virus (EBV), and one ... is a chronic inflammatory disease that destroys the body’s joints. ... patients have high concentrations of EBV DNA in their bodies ...
Breaking Biology Technology:A deeper look at interfaces 2Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3
... Technologies Inc. , a provider of medical imaging devices and ... has received a notice from the staff of the ... to delisting after missing another opportunity to file financial reports. ... the quarter ended June 30 would serve as an additional ...
... - A new biofuels company spun out of Lucigen Corp. ... presented with the second of two state grants. , ,C5-6, ... will receive a $115,000 grant as part of the Bio-Based ... was on hand to announce the grant, which is part of ...
... Madison, Wis. - Wisconsin-based high-tech startup and ... far-flung investors. The most recent example of this ... that is developing laboratory tools for analysis of ... of protein targets, quantitative microarrays, and related products, ...
Cached Biology Technology:Madison business receives $115,000 of new state biofuels funding 2Wisconsin start up Primorigen Biosciences corrals out-of-state investment 2
(Date:4/17/2014)... that devastate honeybees in Europe, Asia and the United ... appear to be impacting native honeybee populations at this ... invasive pests include including Nosema microsporidia and ... to be resilient to these invasive pests, which suggests ... in Europe, Asia and the United States currently are ...
(Date:4/17/2014)... warning on the possible effects of gases such as ... that of carbon dioxide. Now a team of Swiss-German ... regenerable electron acceptors which helps explain why large amount ... released to the atmosphere. However, there are worries that ... a vicious cycle to release large amounts of methane ...
(Date:4/17/2014)... of Texas Medical Branch at Galveston are the ... radiation for cervical cancer should begin colorectal cancer ... UTMB researchers, finding a high incidence of secondary ... radiation, offer new recommendations that the younger women ... eight years after their initial cervical cancer diagnosis ...
Breaking Biology News(10 mins):East African honeybees are safe from invasive pests… for now 2East African honeybees are safe from invasive pests… for now 3Methane climate change risk suggested by proof of redox cycling of humic substances 2Radiation therapy for cervical cancer increases risk for colorectal cancer 2
... Aquaculture production of seafood will probably remain the ... according to an assessment published in the January 2009 ... S. Diana of the University of Michigan at Ann ... harmful effects of aquaculture, the technique may, when practiced ...
... Yan Liu imagine and assemble intricate structures on a ... DNA molecule, a versatile building material offering near limitless ... issue of Science , Yan and Liu, researchers ... of Chemistry and Biochemistry, reveal for the first time ...
... Hopkins neuroscientists has worked out how some newly discovered ... with the brain. The report appears online this week ... are a small number of nerve cells in the ... in the retinarods and conesmelanopsin-containing cells are not used ...
Cached Biology News:Aquaculture's growth seen as continuing 2The gold standard: Biodesign Institute researchers use nanoparticles to make 3-D DNA nanotubes 2The gold standard: Biodesign Institute researchers use nanoparticles to make 3-D DNA nanotubes 3Bright lights, not-so-big pupils 2Bright lights, not-so-big pupils 3